China Medical System debuts on SGX

This marks the group’s second market listing.

China Medical System Holdings Limited (CMS), a pharmaceutical company focused on drug innovation and commercialisation, has made its debut on the Singapore Exchange’s Mainboard (SGX-ST) under the symbol “8A8.”

This marks its second stock market listing, following its debut on the Stock Exchange of Hong Kong Limited (HKEX) in 2010.

The Singapore listing did not involve issuing new shares. CGS International Securities Singapore Pte. Ltd. served as the sole issue manager for the listing.

As of 15 July, the group’s market capitalisation stood at $5.2b (HK$31.91b).

The company said it is pushing ahead with commercialisation plans for five drugs and expects two more innovative products to gain approval in China in FY2025.

It also noted efforts to expand its business, supported by product differentiation and expansion to products with consumer attributes and a more proactive execution of its integrated omnichannel marketing strategies.

“To meet the growing pharmaceutical demand, our CDMO facility is planning to expand its manufacturing capability to include nasal spray platforms, cream, and injectable lines beyond its current focus on oral solid dosage forms,” CMS said.

It is also considering a major scale-up of its overall manufacturing capacity by the end of 2028.

($1 = HK$6.11)